Ke Wang1, Panwen Tian1, Yu Fan2, Ye Wang1, Chuntao Liu1. 1. Department of Respiratory Medicine, West China Hospital, Sichuan University Chengdu 610041, Sichuan Province, P.R. China. 2. Department of Radiotherapy, Sichuan Cancer Hospital Chengdu 610041, Sichuan Province, P.R. China.
Abstract
AIM: To evaluate the best second-line treatments for patients with uncontrolled moderate asthma. METHODS: A single-center, random study was conducted in adult patients with uncontrolled moderate asthma to evaluate the effects of add-on treatments. After add-on treatments for 4 and 12 weeks, the concentration of exhaled nitric oxide (FeNO), average daily durnal peak expiratory flow (PEF) variability and asthma control test (ACT) score were measured. RESULTS:94 patients have been divided into three groups to take different add-on treatments, in tiotropium bromide group, montelukast sodium group and double-dose inhaled corticosteroid (ICS) group. After four weeks, most patients improved their symptoms and ACT scores, with lower concentration of FeNO and small PEF variability. In double-dose ICS group, almost all patients took the complete controls of asthma, compared to those in other two groups. After additional 12 weeks' therapy, patients in all three groups nearly achieved complete controls of asthma. There were two patients with pneumonia in double-dose ICS group. Patients in double-dose ICS group had higher ACT scores, lower concentrations of FeNO and smaller PEF variabilities, but a higher risk of pneumonia, compared to those in other two groups. The differences of PEF variabilities and ACT scores between tiotropium group and double-dose ICS group were not significant. CONCLUSION:Tiotropium in combination with ICS plus LABA showed the similar effects with double-dose ICS plus LABA, without adverse effects, which might be the best option for optimal control of asthma.
RCT Entities:
AIM: To evaluate the best second-line treatments for patients with uncontrolled moderate asthma. METHODS: A single-center, random study was conducted in adult patients with uncontrolled moderate asthma to evaluate the effects of add-on treatments. After add-on treatments for 4 and 12 weeks, the concentration of exhaled nitric oxide (FeNO), average daily durnal peak expiratory flow (PEF) variability and asthma control test (ACT) score were measured. RESULTS: 94 patients have been divided into three groups to take different add-on treatments, in tiotropium bromide group, montelukast sodium group and double-dose inhaled corticosteroid (ICS) group. After four weeks, most patients improved their symptoms and ACT scores, with lower concentration of FeNO and small PEF variability. In double-dose ICS group, almost all patients took the complete controls of asthma, compared to those in other two groups. After additional 12 weeks' therapy, patients in all three groups nearly achieved complete controls of asthma. There were two patients with pneumonia in double-dose ICS group. Patients in double-dose ICS group had higher ACT scores, lower concentrations of FeNO and smaller PEF variabilities, but a higher risk of pneumonia, compared to those in other two groups. The differences of PEF variabilities and ACT scores between tiotropium group and double-dose ICS group were not significant. CONCLUSION: Tiotropium in combination with ICS plus LABA showed the similar effects with double-dose ICS plus LABA, without adverse effects, which might be the best option for optimal control of asthma.
Authors: Persijn J Honkoop; D Robin Taylor; Andrew D Smith; Jiska B Snoeck-Stroband; Jacob K Sont Journal: Eur Respir J Date: 2012-05-31 Impact factor: 16.671
Authors: Huib A M Kerstjens; Michael Engel; Ronald Dahl; Pierluigi Paggiaro; Ekkehard Beck; Mark Vandewalker; Ralf Sigmund; Wolfgang Seibold; Petra Moroni-Zentgraf; Eric D Bateman Journal: N Engl J Med Date: 2012-09-02 Impact factor: 91.245
Authors: Huib A M Kerstjens; Thomas B Casale; Eugene R Bleecker; Eli O Meltzer; Emilio Pizzichini; Olaf Schmidt; Michael Engel; Loek Bour; Cynthia B Verkleij; Petra Moroni-Zentgraf; Eric D Bateman Journal: Lancet Respir Med Date: 2015-02-12 Impact factor: 30.700
Authors: Eric D Bateman; Oliver Kornmann; Peter Schmidt; Anna Pivovarova; Michael Engel; Leonardo M Fabbri Journal: J Allergy Clin Immunol Date: 2011-08 Impact factor: 10.793
Authors: Eric D Bateman; Homer A Boushey; Jean Bousquet; William W Busse; Tim J H Clark; Romain A Pauwels; Søren E Pedersen Journal: Am J Respir Crit Care Med Date: 2004-07-15 Impact factor: 21.405
Authors: David Price; Alan Kaplan; Rupert Jones; Daryl Freeman; Anne Burden; Shuna Gould; Julie von Ziegenweidt; Muzammil Ali; Christine King; Mike Thomas Journal: J Asthma Allergy Date: 2015-01-14
Authors: David Price; Leonard Fromer; Alan Kaplan; Thys van der Molen; Miguel Román-Rodríguez Journal: NPJ Prim Care Respir Med Date: 2014-07-17 Impact factor: 2.871
Authors: Diana M Sobieraj; William L Baker; Elaine Nguyen; Erin R Weeda; Craig I Coleman; C Michael White; Stephen C Lazarus; Kathryn V Blake; Jason E Lang Journal: JAMA Date: 2018-04-10 Impact factor: 56.272
Authors: Michelle M Cloutier; Alan P Baptist; Kathryn V Blake; Edward G Brooks; Tyra Bryant-Stephens; Emily DiMango; Anne E Dixon; Kurtis S Elward; Tina Hartert; Jerry A Krishnan; Robert F Lemanske; Daniel R Ouellette; Wilson D Pace; Michael Schatz; Neil S Skolnik; James W Stout; Stephen J Teach; Craig A Umscheid; Colin G Walsh Journal: J Allergy Clin Immunol Date: 2020-12 Impact factor: 10.793